Total income up 7.1%, margin at 26.2%- Cipla

Total income up 7.1%, margin at 26.2%; Q3 exports up 6%; forex loss Rs 24 Cr in Q3; negotiations for supply contracts are on; EU inhaler launch on track, completely regulatory work: Cipla

Amar Lulla, CEO of Cipla said that total income has grown 7.1%. Domestic operations has grown by 14% and exports by 6%. Income from opertaions stood up 7.1% (YoY). Exports stood up 6% (YoY). Margins stood at 26.2%. ARV sales have cautiously optimized by not participating in low margin tenders. The company suffered a forex loss of Rs 24 crore this quarter.

He further said that negotiations for supply contracts are going on. Most of the big pharma companies are looking at emerging markets and Cipla could see deals conclude with one or 2 of them. He said that Inhaler launch is on track in European Union and the company has completely down all regulatory work, and is waiting for approvals. The launch of ingalers could be seen in 2010 in European Union. The company will launch bio-similairs after one year in India. Salbutamol has been launched in the UK. Cipla is not participating in ARV tenders, he added.

Cipla Q3FY10 net sales (YoY) stood at Rs 1,344.2 crore Vs Rs 1,264.3 crore and net profit stood at Rs 289 crore Vs Rs 223.4 crore.

No related posts.